摘要
[目的]探讨多西他赛联合奥沙利铂并同步放疗治疗局部晚期宫颈鳞癌患者的近期疗效及安全性。[方法]选取2013年7月至2015年1月本院收治的局部晚期宫颈鳞癌患者125例，根据不同治疗方法，将125例患者分为顺铂组（59例）和多西他赛＋奥沙利铂组（TP组）（66例），顺铂组给予放疗＋顺铂单药同步化疗，TP组给予放疗＋多西他赛联合奥沙利铂同步化疗，比较两组近期疗效及不良反应发生率。[结果]TP组的总有效率为93．9％（62／66），明显高于顺铂组8i．3％（48／59），其差异具有统计学意义（P〈0．05）；TP组胃肠道反应、骨髓抑制、放射性直肠炎和放射性膀胱炎的发生率分别为83．3％、98．5％、95．5％和66．7％，而顺铂组则分别为的9i．5％、96．6％、91．5％和54．2％，两组比较差异无统计学意义（P〉0．05）。[结论]多西他赛联合奥沙利铂并同步放疗用于局部晚期宫颈鳞癌的治疗安全、有效，值得临床推广应用。
[Objective]To investigate the clinical efficacy of docetaxel combined with oxaliplatin chemotherapy con- current with radiotherapy for advanced cervical squamous-eell carcinoma. [Methods]One hundred and twenty-five patients with locally advanced cervical squamous carcinoma in our hospital between July 2013-January 2015 were selected as the research subject. According to different therapeutic methods, patients were divided into the cisplatin group （59 cases） and Docetaxel＆Oxaliplatin group （TP group, 66 cases）. The cisplatin group was given cisplatin chemotherapy concurrent with radiation therapy, while TP group was given docetaxel combined with oxaliplatin chemotherapy concurrent with ra- diotherapy. The curative effect and adverse reactions between the two groups were observed. [Results]The total effective rate of TP group was 93.9% （62/66）, which was significantly higher than that of the cisplatin group （81.3%, 48/59） ; the difference was statistically significant （ P〈0.05）. The occurrence of gastrointestinal reaction, myelosuppression, radiation proctitis, and radiocystitis of TP group were 83.3 %, 98.5 %, 95.5 % and 66.7 %, respectively, while those in the cisplatin group were 91.5%, 96.6%, 91.5%, and 54.2%, respectively. There were no significantly statistical differences between the two groups （ P 〉0.05）. [Conclusion]Docetaxel combined with oxaliplatin chemotherapy concurrent with ra- diotherapy for locally advanced cervical squamous cell carcinoma is both safe and effective.
出处
《医学临床研究》
CAS
2017年第3期441-443,共3页
Journal of Clinical Research
